論文

査読有り 国際誌
2020年3月15日

Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant.

Pharmaceutics
  • Sayami Ito
  • Sachiko Hirobe
  • Takuto Kawakita
  • Mio Saito
  • Ying-Shu Quan
  • Fumio Kamiyama
  • Ken J Ishii
  • Mizuho Nagao
  • Takao Fujisawa
  • Masashi Tachibana
  • Naoki Okada
  • 全て表示

12
3
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.3390/pharmaceutics12030267
出版者・発行元
MDPI

Transcutaneous immunization (TCI) is easy to use, minimally invasive, and has excellent efficacy in vaccines against infections. We focused on toll-like receptor (TLR) ligands as applicable adjuvants for transcutaneous formulations and characterized immune responses. TCI was performed using poke-and-patch methods, in which puncture holes are formed with a polyglycolic acid microneedle on the back skin of mice. Various TLR ligands were applied to the puncture holes and covered with an ovalbumin-loaded hydrophilic gel patch. During the screening process, K3 (CpG-oligonucleotide) successfully produced more antigen-specific antibodies than other TLR ligands and induced T helper (Th) 1-type polarization. Transcutaneously administered K3 was detected in draining lymph nodes and was found to promote B cell activation and differentiation, suggesting a direct transcutaneous adjuvant activity on B cells. Furthermore, a human safety test of K3-loaded self-dissolving microneedles (sdMN) was performed. Although a local skin reaction was observed at the sdMN application site, there was no systemic side reaction. In summary, we report a K3-induced Th1-type immune response that is a promising adjuvant for transcutaneous vaccine formulations using MN and show that K3-loaded sdMN can be safely applied to human skin.

リンク情報
DOI
https://doi.org/10.3390/pharmaceutics12030267
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32183437
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151019
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000526541000041&DestApp=WOS_CPL
URL
https://www.mdpi.com/1999-4923/12/3/267
ID情報
  • DOI : 10.3390/pharmaceutics12030267
  • eISSN : 1999-4923
  • ORCIDのPut Code : 70841248
  • PubMed ID : 32183437
  • PubMed Central 記事ID : PMC7151019
  • Web of Science ID : WOS:000526541000041

エクスポート
BibTeX RIS